PhRMA Meets With Indian Officials To Discuss Compulsory Licensing
Executives of the Pharmaceutical Research and Manufacturers of America were in India the last two weeks of October for meetings with member companies. One issue had grabbed their attention: India’s move toward compulsory licensing.
You may also be interested in...
The Department of Industrial Policy and Promotion is analyzing and interpreting comments on a contentious subject that has kept Indian and multinational drug firms bitterly divided for more than five years, while forcing the government into a dilemma over an acceptable policy.
Enrollment-boosting strategy backed by industry rep at Duke-Margolis meeting as FDA official suggests having sponsors develop study plans for pregnant and lactating women with ‘elements of’ the requirement for pediatric studies.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.